Savara Inc Paid-in-Kind Interest
Savara Inc (SVRA) reported Paid-in-Kind Interest of $243.00 thousand for the 9-month period ending 2020-09-30, per its 10-Q filed 2021-11-12.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:PaidInKindInterest · last filed 2021-11-12
- Savara Inc paid-in-kind interest for the quarter ending 2020-09-30 was $100.00K.
- Savara Inc paid-in-kind interest for the quarter ending 2020-06-30 was $10.00K.
- Savara Inc paid-in-kind interest for the quarter ending 2020-03-31 was $133.00K.
- Savara Inc paid-in-kind interest for the quarter ending 2018-12-31 was -$8.00K.
- Savara Inc paid-in-kind interest for fiscal 2018 was $75.00K, a 77.68% decline from fiscal 2017.
- Savara Inc paid-in-kind interest for fiscal 2017 was $336.00K, a 68.84% increase from fiscal 2016.
- Savara Inc paid-in-kind interest for fiscal 2016 was $199.00K, a 69.00% decline from fiscal 2015.
- Savara Inc paid-in-kind interest for fiscal 2015 was $642.00K.
| Period end | Paid-in-Kind Interest 3 month | Paid-in-Kind Interest 6 month | Paid-in-Kind Interest 9 month | Paid-in-Kind Interest 12 month |
|---|---|---|---|---|
| 2020-09-30 | $100.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $110.00K derived: sum of 2 quarters · filed 2021-11-12 | $243.00K 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $10.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $143.00K 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | $133.00K 10-Q · filed 2021-05-13 | |||
| 2019-09-30 | $42.00K 10-Q · filed 2020-11-05 | |||
| 2018-12-31 | -$8.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-13 | $21.00K derived: sum of 2 quarters · filed 2019-03-13 | $40.00K derived: sum of 3 quarters · filed 2019-03-13 | $75.00K 10-K · filed 2019-03-13 |
| 2018-09-30 | $29.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $48.00K derived: sum of 2 quarters · filed 2018-11-07 | $83.00K 10-Q · filed 2018-11-07 | $24.00K derived: sum of 4 quarters · filed 2019-03-13 |
| 2018-06-30 | $19.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $54.00K 10-Q · filed 2018-08-09 | -$5.00K derived: sum of 3 quarters · filed 2019-03-13 | -$10.00K derived: sum of 4 quarters · filed 2019-03-13 |
| 2018-03-31 | $35.00K 10-Q · filed 2018-05-09 | -$24.00K derived: sum of 2 quarters · filed 2019-03-13 | -$29.00K derived: sum of 3 quarters · filed 2019-03-13 | $273.00K derived: sum of 4 quarters · filed 2019-03-13 |
| 2017-12-31 | -$59.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-13 | -$64.00K derived: sum of 2 quarters · filed 2019-03-13 | $238.00K derived: sum of 3 quarters · filed 2019-03-13 | $336.00K 10-K · filed 2019-03-13 |
| 2017-09-30 | -$5.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $297.00K derived: sum of 2 quarters · filed 2018-11-07 | $395.00K 10-Q · filed 2018-11-07 | $495.00K derived: sum of 4 quarters · filed 2018-11-07 |
| 2017-06-30 | $302.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $400.00K 10-Q · filed 2018-08-09 | $500.00K derived: sum of 3 quarters · filed 2018-08-09 | $573.00K derived: sum of 4 quarters · filed 2018-08-09 |
| 2017-03-31 | $98.00K 10-Q · filed 2018-05-09 | $198.00K derived: sum of 2 quarters · filed 2018-05-09 | $271.00K derived: sum of 3 quarters · filed 2018-05-09 | |
| 2016-12-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-14 | $173.00K derived: sum of 2 quarters · filed 2018-03-14 | $199.00K 10-K · filed 2018-03-14 | |
| 2016-09-30 | $73.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $99.00K 10-Q · filed 2017-11-08 | ||
| 2016-06-30 | $26.00K 10-Q · filed 2017-08-09 | |||
| 2015-12-31 | $642.00K 10-K · filed 2018-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B |